Talazoparib is approved for the treatment of germline BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, with ongoing studies exploring its efficacy in ovarian cancer. Here, ERBB2 is linked to ovarian carcinoma.